Brief: Richter, CSL subsidiary sign schizophrenia drug sale deal

Gedeon Richter

24/05/2019 07:08

May 24 (Reuters) - Hungary's Gedeon Richter Plc  GDRB.BU 
says in statement published on Budapest Stock Exchange web site:
    * SIGNS LICENSE AGREEMENT TO COMMERCIALISE SCHIZOPHRENIA
DRUG
CARIPRAZINE IN AUSTRALIA AND NEW ZEALAND WITH CSL  CSL.AX 
SUBSIDIARY SEQIRUS
    * EXCLUSIVE AGREEMENT SAYS RICHTER RESPONSIBLE FOR PRODUCT
SUPPLY,
SEQIRUS FOR REGISTRATION AND COMMERCIALISATION IN AUSTRALIA, NEW
ZEALAND
    * RICHTER WILL RECEIVE UNSPECIFIED UPFRONT PAYMENT AND
MILESTONE
PAYMENTS FROM SEQIRUS

Further company coverage:  GDRB.BU   CSL.AX 

 (Reporting by Marton Dunai)
 ((marton.dunai@thomsonreuters.com;))